APO Research
Talk to an analyst

APO RESEARCH · REPORT

Passive Immunizing Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Passive Immunizing Drugs Market Outlook and Growth Opportunities 2026

27 December 2025209 pages

Choose your research edition.

Industry ResearchPassive Immunizing Drugs Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Passive Immunizing Drugs Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Passive Immunizing Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Passive Immunizing Drugs Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Passive Immunizing Drugs Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Passive Immunizing Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Passive Immunizing Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Passive Immunizing Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Passive Immunizing Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Passive Immunizing Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Passive Immunizing Drugs market include Xingmeng Biopharmaceuticals (Suzhou), Wuhan Institute of Biological Products, Sichuan Yuanda Shuyang Pharmaceutical, Shanxi Kangbao Biological Product, Sharon Bio-Medicine, Hualan Biological Engineering, North China Pharmaceutical, Sinopharm Group and Zydus Lifesciences, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Passive Immunizing Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Passive Immunizing Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Passive Immunizing Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Passive Immunizing Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Passive Immunizing Drugs Segment by Company

Xingmeng Biopharmaceuticals (Suzhou)

Wuhan Institute of Biological Products

Sichuan Yuanda Shuyang Pharmaceutical

Shanxi Kangbao Biological Product

Sharon Bio-Medicine

Hualan Biological Engineering

North China Pharmaceutical

Sinopharm Group

Zydus Lifesciences

Serum Institute of India

Sanofi Pasteur

Kedrion Biopharma

Kamada

Haffkine Bio-Pharmaceutical

Grifols

Bharat Biotech

Passive Immunizing Drugs Segment by Type

Rabies Immunoglobulin

Rabies Virus Monoclonal Antibody

Anti-rabies Serum

Passive Immunizing Drugs Segment by Application

Category II Exposure

Category III Exposure

Passive Immunizing Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Passive Immunizing Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Passive Immunizing Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Passive Immunizing Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Passive Immunizing Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Passive Immunizing Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Passive Immunizing Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Passive Immunizing Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Passive Immunizing Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Passive Immunizing Drugs industry.

Chapter 3: Detailed analysis of Passive Immunizing Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Passive Immunizing Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Passive Immunizing Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Passive Immunizing Drugs Industry Trends Table 2. Passive Immunizing Drugs Industry Drivers Table 3. Passive Immunizing Drugs Industry Opportunities and Challenges Table 4. Passive Immunizing Drugs Industry Restraints Table 5. Global Passive Immunizing Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Passive Immunizing Drugs Revenue Share by Company (2021-2026) Table 7. Global Passive Immunizing Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Passive Immunizing Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Passive Immunizing Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Passive Immunizing Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Passive Immunizing Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Passive Immunizing Drugs Company, Product Type & Application Table 13. Global Passive Immunizing Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Passive Immunizing Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Rabies Immunoglobulin Table 18. Significant Companies of Rabies Virus Monoclonal Antibody Table 19. Significant Companies of Anti-rabies Serum Table 20. Global Passive Immunizing Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Passive Immunizing Drugs Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Passive Immunizing Drugs Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Passive Immunizing Drugs Sales Volume Share by Type (2021-2026) Table 24. Global Passive Immunizing Drugs Sales Volume Share by Type (2027-2032) Table 25. Global Passive Immunizing Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Passive Immunizing Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Passive Immunizing Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Passive Immunizing Drugs Sales Value Share by Type (2021-2026) Table 29. Global Passive Immunizing Drugs Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Category II Exposure Table 31. Significant Companies of Category III Exposure Table 32. Global Passive Immunizing Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Passive Immunizing Drugs Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Passive Immunizing Drugs Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Passive Immunizing Drugs Sales Volume Share by Application (2021-2026) Table 36. Global Passive Immunizing Drugs Sales Volume Share by Application (2027-2032) Table 37. Global Passive Immunizing Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Passive Immunizing Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Passive Immunizing Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Passive Immunizing Drugs Sales Value Share by Application (2021-2026) Table 41. Global Passive Immunizing Drugs Sales Value Share by Application (2027-2032) Table 42. Global Passive Immunizing Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Passive Immunizing Drugs Sales by Region (2021-2026) & (K Units) Table 44. Global Passive Immunizing Drugs Sales Market Share by Region (2021-2026) Table 45. Global Passive Immunizing Drugs Sales by Region (2027-2032) & (K Units) Table 46. Global Passive Immunizing Drugs Sales Market Share by Region (2027-2032) Table 47. Global Passive Immunizing Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Passive Immunizing Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Passive Immunizing Drugs Sales Value Share by Region (2021-2026) Table 50. Global Passive Immunizing Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Passive Immunizing Drugs Sales Value Share by Region (2027-2032) Table 52. Global Passive Immunizing Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Passive Immunizing Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Passive Immunizing Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Passive Immunizing Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Passive Immunizing Drugs Sales by Country (2021-2026) & (K Units) Table 57. Global Passive Immunizing Drugs Sales Market Share by Country (2021-2026) Table 58. Global Passive Immunizing Drugs Sales by Country (2027-2032) & (K Units) Table 59. Global Passive Immunizing Drugs Sales Market Share by Country (2027-2032) Table 60. Global Passive Immunizing Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Passive Immunizing Drugs Sales Value Market Share by Country (2021-2026) Table 62. Global Passive Immunizing Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Passive Immunizing Drugs Sales Value Market Share by Country (2027-2032) Table 64. Xingmeng Biopharmaceuticals (Suzhou) Company Information Table 65. Xingmeng Biopharmaceuticals (Suzhou) Business Overview Table 66. Xingmeng Biopharmaceuticals (Suzhou) Passive Immunizing Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Xingmeng Biopharmaceuticals (Suzhou) Passive Immunizing Drugs Product Portfolio Table 68. Xingmeng Biopharmaceuticals (Suzhou) Recent Development Table 69. Wuhan Institute of Biological Products Company Information Table 70. Wuhan Institute of Biological Products Business Overview Table 71. Wuhan Institute of Biological Products Passive Immunizing Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Wuhan Institute of Biological Products Passive Immunizing Drugs Product Portfolio Table 73. Wuhan Institute of Biological Products Recent Development Table 74. Sichuan Yuanda Shuyang Pharmaceutical Company Information Table 75. Sichuan Yuanda Shuyang Pharmaceutical Business Overview Table 76. Sichuan Yuanda Shuyang Pharmaceutical Passive Immunizing Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Sichuan Yuanda Shuyang Pharmaceutical Passive Immunizing Drugs Product Portfolio Table 78. Sichuan Yuanda Shuyang Pharmaceutical Recent Development Table 79. Shanxi Kangbao Biological Product Company Information Table 80. Shanxi Kangbao Biological Product Business Overview Table 81. Shanxi Kangbao Biological Product Passive Immunizing Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Shanxi Kangbao Biological Product Passive Immunizing Drugs Product Portfolio Table 83. Shanxi Kangbao Biological Product Recent Development Table 84. Sharon Bio-Medicine Company Information Table 85. Sharon Bio-Medicine Business Overview Table 86. Sharon Bio-Medicine Passive Immunizing Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Sharon Bio-Medicine Passive Immunizing Drugs Product Portfolio Table 88. Sharon Bio-Medicine Recent Development Table 89. Hualan Biological Engineering Company Information Table 90. Hualan Biological Engineering Business Overview Table 91. Hualan Biological Engineering Passive Immunizing Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Hualan Biological Engineering Passive Immunizing Drugs Product Portfolio Table 93. Hualan Biological Engineering Recent Development Table 94. North China Pharmaceutical Company Information Table 95. North China Pharmaceutical Business Overview Table 96. North China Pharmaceutical Passive Immunizing Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. North China Pharmaceutical Passive Immunizing Drugs Product Portfolio Table 98. North China Pharmaceutical Recent Development Table 99. Sinopharm Group Company Information Table 100. Sinopharm Group Business Overview Table 101. Sinopharm Group Passive Immunizing Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Sinopharm Group Passive Immunizing Drugs Product Portfolio Table 103. Sinopharm Group Recent Development Table 104. Zydus Lifesciences Company Information Table 105. Zydus Lifesciences Business Overview Table 106. Zydus Lifesciences Passive Immunizing Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Zydus Lifesciences Passive Immunizing Drugs Product Portfolio Table 108. Zydus Lifesciences Recent Development Table 109. Serum Institute of India Company Information Table 110. Serum Institute of India Business Overview Table 111. Serum Institute of India Passive Immunizing Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Serum Institute of India Passive Immunizing Drugs Product Portfolio Table 113. Serum Institute of India Recent Development Table 114. Sanofi Pasteur Company Information Table 115. Sanofi Pasteur Business Overview Table 116. Sanofi Pasteur Passive Immunizing Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Sanofi Pasteur Passive Immunizing Drugs Product Portfolio Table 118. Sanofi Pasteur Recent Development Table 119. Kedrion Biopharma Company Information Table 120. Kedrion Biopharma Business Overview Table 121. Kedrion Biopharma Passive Immunizing Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Kedrion Biopharma Passive Immunizing Drugs Product Portfolio Table 123. Kedrion Biopharma Recent Development Table 124. Kamada Company Information Table 125. Kamada Business Overview Table 126. Kamada Passive Immunizing Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Kamada Passive Immunizing Drugs Product Portfolio Table 128. Kamada Recent Development Table 129. Haffkine Bio-Pharmaceutical Company Information Table 130. Haffkine Bio-Pharmaceutical Business Overview Table 131. Haffkine Bio-Pharmaceutical Passive Immunizing Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Haffkine Bio-Pharmaceutical Passive Immunizing Drugs Product Portfolio Table 133. Haffkine Bio-Pharmaceutical Recent Development Table 134. Grifols Company Information Table 135. Grifols Business Overview Table 136. Grifols Passive Immunizing Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Grifols Passive Immunizing Drugs Product Portfolio Table 138. Grifols Recent Development Table 139. Bharat Biotech Company Information Table 140. Bharat Biotech Business Overview Table 141. Bharat Biotech Passive Immunizing Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Bharat Biotech Passive Immunizing Drugs Product Portfolio Table 143. Bharat Biotech Recent Development Table 144. Key Raw Materials Table 145. Raw Materials Key Suppliers Table 146. Passive Immunizing Drugs Distributors List Table 147. Passive Immunizing Drugs Customers List Table 148. Research Programs/Design for This Report Table 149. Authors List of This Report Table 150. Secondary Sources Table 151. Primary Sources List of Figures Figure 1. Passive Immunizing Drugs Product Image Figure 2. Global Passive Immunizing Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Passive Immunizing Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Passive Immunizing Drugs Sales (2021-2032) & (K Units) Figure 5. Global Passive Immunizing Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Passive Immunizing Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Rabies Immunoglobulin Image Figure 10. Rabies Virus Monoclonal Antibody Image Figure 11. Anti-rabies Serum Image Figure 12. Global Passive Immunizing Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Passive Immunizing Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Passive Immunizing Drugs Sales Volume Share by Type (2021-2032) Figure 15. Global Passive Immunizing Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Passive Immunizing Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Passive Immunizing Drugs Sales Value Share by Type (2021-2032) Figure 18. Category II Exposure Image Figure 19. Category III Exposure Image Figure 20. Global Passive Immunizing Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Passive Immunizing Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Passive Immunizing Drugs Sales Volume Share by Application (2021-2032) Figure 23. Global Passive Immunizing Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Passive Immunizing Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Passive Immunizing Drugs Sales Value Share by Application (2021-2032) Figure 26. Global Passive Immunizing Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Passive Immunizing Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Passive Immunizing Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Passive Immunizing Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Passive Immunizing Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. North America Passive Immunizing Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Passive Immunizing Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Passive Immunizing Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Passive Immunizing Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Passive Immunizing Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Passive Immunizing Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. South America Passive Immunizing Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Passive Immunizing Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Passive Immunizing Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Passive Immunizing Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Passive Immunizing Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Passive Immunizing Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Passive Immunizing Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Passive Immunizing Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Passive Immunizing Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Passive Immunizing Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Passive Immunizing Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Passive Immunizing Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Passive Immunizing Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Passive Immunizing Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Passive Immunizing Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Passive Immunizing Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Passive Immunizing Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Passive Immunizing Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Passive Immunizing Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Passive Immunizing Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Passive Immunizing Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Passive Immunizing Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Passive Immunizing Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Passive Immunizing Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Passive Immunizing Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Passive Immunizing Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Passive Immunizing Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Passive Immunizing Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Passive Immunizing Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Passive Immunizing Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Passive Immunizing Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Passive Immunizing Drugs Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Passive Immunizing Drugs Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Rabies Immunoglobulin
  • Rabies Virus Monoclonal Antibody
  • Anti-rabies Serum
Applications
  • Category II Exposure
  • Category III Exposure
Companies covered
  • Xingmeng Biopharmaceuticals (Suzhou)
  • Wuhan Institute of Biological Products
  • Sichuan Yuanda Shuyang Pharmaceutical
  • Shanxi Kangbao Biological Product
  • Sharon Bio-Medicine
  • Hualan Biological Engineering
  • North China Pharmaceutical
  • Sinopharm Group
  • Zydus Lifesciences
  • Serum Institute of India
  • Sanofi Pasteur
  • Kedrion Biopharma
  • Kamada
  • Haffkine Bio-Pharmaceutical
  • Grifols
  • Bharat Biotech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Passive Immunizing Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Passive Immunizing Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Passive Immunizing Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Passive Immunizing Drugs Market Dynamics
  1. 2.1 Passive Immunizing Drugs Industry Trends
  2. 2.2 Passive Immunizing Drugs Industry Drivers
  3. 2.3 Passive Immunizing Drugs Industry Opportunities and Challenges
  4. 2.4 Passive Immunizing Drugs Industry Restraints
3 Passive Immunizing Drugs Market by Company
  1. 3.1 Global Passive Immunizing Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Passive Immunizing Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Passive Immunizing Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Passive Immunizing Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Passive Immunizing Drugs Company Ranking (2024-2026)
  6. 3.6 Global Passive Immunizing Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Passive Immunizing Drugs Company Product Type and Application
  8. 3.8 Global Passive Immunizing Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Passive Immunizing Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Passive Immunizing Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Passive Immunizing Drugs Market by Type
  1. 4.1 Passive Immunizing Drugs Type Introduction
  2. 4.1.1 Rabies Immunoglobulin
  3. 4.1.2 Rabies Virus Monoclonal Antibody
  4. 4.1.3 Anti-rabies Serum
  5. 4.2 Global Passive Immunizing Drugs Sales Volume by Type
  6. 4.2.1 Global Passive Immunizing Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Passive Immunizing Drugs Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Passive Immunizing Drugs Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Passive Immunizing Drugs Sales Value by Type
  10. 4.3.1 Global Passive Immunizing Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Passive Immunizing Drugs Sales Value by Type (2021-2032)
  12. 4.3.3 Global Passive Immunizing Drugs Sales Value Share by Type (2021-2032)
5 Passive Immunizing Drugs Market by Application
  1. 5.1 Passive Immunizing Drugs Application Introduction
  2. 5.1.1 Category II Exposure
  3. 5.1.2 Category III Exposure
  4. 5.2 Global Passive Immunizing Drugs Sales Volume by Application
  5. 5.2.1 Global Passive Immunizing Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Passive Immunizing Drugs Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Passive Immunizing Drugs Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Passive Immunizing Drugs Sales Value by Application
  9. 5.3.1 Global Passive Immunizing Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Passive Immunizing Drugs Sales Value by Application (2021-2032)
  11. 5.3.3 Global Passive Immunizing Drugs Sales Value Share by Application (2021-2032)
6 Passive Immunizing Drugs Regional Sales and Value Analysis
  1. 6.1 Global Passive Immunizing Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Passive Immunizing Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Passive Immunizing Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Passive Immunizing Drugs Sales by Region (2027-2032)
  5. 6.3 Global Passive Immunizing Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Passive Immunizing Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Passive Immunizing Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Passive Immunizing Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Passive Immunizing Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Passive Immunizing Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Passive Immunizing Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Passive Immunizing Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Passive Immunizing Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Passive Immunizing Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Passive Immunizing Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Passive Immunizing Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Passive Immunizing Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Passive Immunizing Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Passive Immunizing Drugs Sales Value Share by Country, 2025 VS 2032
7 Passive Immunizing Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Passive Immunizing Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Passive Immunizing Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Passive Immunizing Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Passive Immunizing Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Passive Immunizing Drugs Sales by Country (2027-2032)
  6. 7.4 Global Passive Immunizing Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Passive Immunizing Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Passive Immunizing Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Passive Immunizing Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Passive Immunizing Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Passive Immunizing Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Passive Immunizing Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Passive Immunizing Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Passive Immunizing Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Passive Immunizing Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Passive Immunizing Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Passive Immunizing Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Passive Immunizing Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Passive Immunizing Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Passive Immunizing Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Passive Immunizing Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Passive Immunizing Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Passive Immunizing Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Passive Immunizing Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Passive Immunizing Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Passive Immunizing Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Passive Immunizing Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Passive Immunizing Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Passive Immunizing Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Passive Immunizing Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Passive Immunizing Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Passive Immunizing Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Passive Immunizing Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Passive Immunizing Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Passive Immunizing Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Passive Immunizing Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Passive Immunizing Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Passive Immunizing Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Xingmeng Biopharmaceuticals (Suzhou)
  2. 8.1.1 Xingmeng Biopharmaceuticals (Suzhou) Company Information
  3. 8.1.2 Xingmeng Biopharmaceuticals (Suzhou) Business Overview
  4. 8.1.3 Xingmeng Biopharmaceuticals (Suzhou) Passive Immunizing Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Xingmeng Biopharmaceuticals (Suzhou) Passive Immunizing Drugs Product Portfolio
  6. 8.1.5 Xingmeng Biopharmaceuticals (Suzhou) Recent Developments
  7. 8.2 Wuhan Institute of Biological Products
  8. 8.2.1 Wuhan Institute of Biological Products Company Information
  9. 8.2.2 Wuhan Institute of Biological Products Business Overview
  10. 8.2.3 Wuhan Institute of Biological Products Passive Immunizing Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Wuhan Institute of Biological Products Passive Immunizing Drugs Product Portfolio
  12. 8.2.5 Wuhan Institute of Biological Products Recent Developments
  13. 8.3 Sichuan Yuanda Shuyang Pharmaceutical
  14. 8.3.1 Sichuan Yuanda Shuyang Pharmaceutical Company Information
  15. 8.3.2 Sichuan Yuanda Shuyang Pharmaceutical Business Overview
  16. 8.3.3 Sichuan Yuanda Shuyang Pharmaceutical Passive Immunizing Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sichuan Yuanda Shuyang Pharmaceutical Passive Immunizing Drugs Product Portfolio
  18. 8.3.5 Sichuan Yuanda Shuyang Pharmaceutical Recent Developments
  19. 8.4 Shanxi Kangbao Biological Product
  20. 8.4.1 Shanxi Kangbao Biological Product Company Information
  21. 8.4.2 Shanxi Kangbao Biological Product Business Overview
  22. 8.4.3 Shanxi Kangbao Biological Product Passive Immunizing Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Shanxi Kangbao Biological Product Passive Immunizing Drugs Product Portfolio
  24. 8.4.5 Shanxi Kangbao Biological Product Recent Developments
  25. 8.5 Sharon Bio-Medicine
  26. 8.5.1 Sharon Bio-Medicine Company Information
  27. 8.5.2 Sharon Bio-Medicine Business Overview
  28. 8.5.3 Sharon Bio-Medicine Passive Immunizing Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Sharon Bio-Medicine Passive Immunizing Drugs Product Portfolio
  30. 8.5.5 Sharon Bio-Medicine Recent Developments
  31. 8.6 Hualan Biological Engineering
  32. 8.6.1 Hualan Biological Engineering Company Information
  33. 8.6.2 Hualan Biological Engineering Business Overview
  34. 8.6.3 Hualan Biological Engineering Passive Immunizing Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Hualan Biological Engineering Passive Immunizing Drugs Product Portfolio
  36. 8.6.5 Hualan Biological Engineering Recent Developments
  37. 8.7 North China Pharmaceutical
  38. 8.7.1 North China Pharmaceutical Company Information
  39. 8.7.2 North China Pharmaceutical Business Overview
  40. 8.7.3 North China Pharmaceutical Passive Immunizing Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 North China Pharmaceutical Passive Immunizing Drugs Product Portfolio
  42. 8.7.5 North China Pharmaceutical Recent Developments
  43. 8.8 Sinopharm Group
  44. 8.8.1 Sinopharm Group Company Information
  45. 8.8.2 Sinopharm Group Business Overview
  46. 8.8.3 Sinopharm Group Passive Immunizing Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Sinopharm Group Passive Immunizing Drugs Product Portfolio
  48. 8.8.5 Sinopharm Group Recent Developments
  49. 8.9 Zydus Lifesciences
  50. 8.9.1 Zydus Lifesciences Company Information
  51. 8.9.2 Zydus Lifesciences Business Overview
  52. 8.9.3 Zydus Lifesciences Passive Immunizing Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Zydus Lifesciences Passive Immunizing Drugs Product Portfolio
  54. 8.9.5 Zydus Lifesciences Recent Developments
  55. 8.10 Serum Institute of India
  56. 8.10.1 Serum Institute of India Company Information
  57. 8.10.2 Serum Institute of India Business Overview
  58. 8.10.3 Serum Institute of India Passive Immunizing Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Serum Institute of India Passive Immunizing Drugs Product Portfolio
  60. 8.10.5 Serum Institute of India Recent Developments
  61. 8.11 Sanofi Pasteur
  62. 8.11.1 Sanofi Pasteur Company Information
  63. 8.11.2 Sanofi Pasteur Business Overview
  64. 8.11.3 Sanofi Pasteur Passive Immunizing Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Sanofi Pasteur Passive Immunizing Drugs Product Portfolio
  66. 8.11.5 Sanofi Pasteur Recent Developments
  67. 8.12 Kedrion Biopharma
  68. 8.12.1 Kedrion Biopharma Company Information
  69. 8.12.2 Kedrion Biopharma Business Overview
  70. 8.12.3 Kedrion Biopharma Passive Immunizing Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Kedrion Biopharma Passive Immunizing Drugs Product Portfolio
  72. 8.12.5 Kedrion Biopharma Recent Developments
  73. 8.13 Kamada
  74. 8.13.1 Kamada Company Information
  75. 8.13.2 Kamada Business Overview
  76. 8.13.3 Kamada Passive Immunizing Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Kamada Passive Immunizing Drugs Product Portfolio
  78. 8.13.5 Kamada Recent Developments
  79. 8.14 Haffkine Bio-Pharmaceutical
  80. 8.14.1 Haffkine Bio-Pharmaceutical Company Information
  81. 8.14.2 Haffkine Bio-Pharmaceutical Business Overview
  82. 8.14.3 Haffkine Bio-Pharmaceutical Passive Immunizing Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Haffkine Bio-Pharmaceutical Passive Immunizing Drugs Product Portfolio
  84. 8.14.5 Haffkine Bio-Pharmaceutical Recent Developments
  85. 8.15 Grifols
  86. 8.15.1 Grifols Company Information
  87. 8.15.2 Grifols Business Overview
  88. 8.15.3 Grifols Passive Immunizing Drugs Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Grifols Passive Immunizing Drugs Product Portfolio
  90. 8.15.5 Grifols Recent Developments
  91. 8.16 Bharat Biotech
  92. 8.16.1 Bharat Biotech Company Information
  93. 8.16.2 Bharat Biotech Business Overview
  94. 8.16.3 Bharat Biotech Passive Immunizing Drugs Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Bharat Biotech Passive Immunizing Drugs Product Portfolio
  96. 8.16.5 Bharat Biotech Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Passive Immunizing Drugs Value Chain Analysis
  2. 9.1.1 Passive Immunizing Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Passive Immunizing Drugs Sales Mode & Process
  6. 9.2 Passive Immunizing Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Passive Immunizing Drugs Distributors
  9. 9.2.3 Passive Immunizing Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst